Eligibility International Travellers whose sole objective of visiting India is recreation , sight-seeing , casual visit to meet friends or relatives, short duration medical treatment or casual business visit.https://indianvisaonline.gov.in/visa/tvoa.html That this facility is being given to 130 odd countries is better still
Albania, Andorra, Anguilla, Antigua & Barbuda, Argentina, Armenia, Aruba, Australia, Austria, Bahamas, Barbados, Belgium, Belize, Bolivia, Bosnia & Herzegovina, Botswana, Brazil, Brunei, Bulgaria, Cambodia, Canada, Cape Verde, Cayman Island, Chile, China, China- SAR Hong-Kong, China- SAR Macau, Colombia, Comoros, Cook Islands, Costa Rica, Cote d lvoire, Croatia, Cuba, Czech Republic, Denmark, Djibouti, Dominica, Dominican Republic, East Timor, Ecuador, El Salvador, Eritrea, Estonia, Fiji, Finland, France, Gabon, Gambia, Georgia, Germany, Ghana, Greece, Grenada, Guatemala, Guinea, Guyana, Haiti, Honduras, Hungary, Iceland, Indonesia, Ireland, Israel, Jamaica, Japan, Jordan, Kenya, Kiribati, Laos, Latvia, Lesotho, Liberia, Liechtenstein, Lithuania, Luxembourg, Madagascar, Malawi, Malaysia, Malta, Marshall Islands, Mauritius, Mexico, Micronesia, Moldova, Monaco, Mongolia, Montenegro, Montserrat, Mozambique, Myanmar, Namibia, Nauru, Netherlands, New Zealand, Nicaragua, Niue Island, Norway, Oman, Palau, Palestine, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Republic of Korea, Republic of Macedonia, Romania, Russia, Saint Christopher and Nevis, Saint Lucia, Saint Vincent & the Grenadines, Samoa, San Marino, Senegal, Serbia, Seychelles, Singapore, Slovakia, Slovenia, Solomon Islands, South Africa, Spain, Sri Lanka, Suriname, Swaziland, Sweden, Switzerland, Taiwan, Tajikistan, Tanzania, Thailand, Tonga, Trinidad & Tobago, Turks & Caicos Island, Tuvalu, UAE, Ukraine, United Kingdom, Uruguay, USA, Vanuatu, Vatican City-Holy See, Venezuela, Vietnam, Zambia and Zimbabwe.This should make it somewhat easier for any Indian organizer as well as any participants from any of the member countries shared. There is possibility that this list would even get longer, provided we are able to scale our airports and all and any necessary infrastructure that would be needed for International Visitors to have a good experience. What has been particularly interesting is to know which ports of call are being used by International Visitors as well as overall growth rate
The Percentage share of Foreign Tourist Arrivals (FTAs) in India during November, 2016 among the top 15 source countries was highest from USA (15.53%) followed by UK (11.21%), Bangladesh (10.72%), Canada (4.66%), Russian Fed (4.53%), Australia (4.04%), Malaysia (3.65%), Germany (3.53%), China (3.14%), France (2.88%), Sri Lanka (2.49%), Japan (2.49%), Singapore (2.16%), Nepal (1.46%) and Thailand (1.37%).And port of call
The Percentage share of Foreign Tourist Arrivals (FTAs) in India during November 2016 among the top 15 ports was highest at Delhi Airport (32.71%) followed by Mumbai Airport (18.51%), Chennai Airport (6.83%), Bengaluru Airport (5.89%), Haridaspur Land check post (5.87%), Goa Airport (5.63%), Kolkata Airport (3.90%), Cochin Airport (3.29%), Hyderabad Airport (3.14%), Ahmadabad Airport (2.76%), Trivandrum Airport (1.54%), Trichy Airport (1.53%), Gede Rail (1.16%), Amritsar Airport (1.15%), and Ghojadanga land check post (0.82%) .The Ghojadanga land check post seems to be between West Bengal, India and Bangladesh. Gede Railway Station is also in West Bengal as well. So all and any overlanders could take any of those ways.Even Hardispur Land Check post comes in the Bengal-Bangladesh border only. In the airports, Delhi Airport seems to be attracting lot more business than the Mumbai Airport. Part of the reason I *think* is the direct link of Delhi Airport to NDLS via the Delhi Airport Express Line . The same when it will happen in Mumbai should be a game-changer for city too. Now if you are wondering why I have been suddenly talking about visas and airports in India, it came because Hong Kong is going to Withdraw Visa Free Entry Facility For Indians. Although, as rightly pointed out in the article doesn t make sense from economic POV and seems to be somewhat politically motivated. Not that I or anybody else can do anything about that. Seeing that, I thought it was a good opportunity to see how good/Bad our Government is and it seems to be on the right path. Although the hawks (Intelligence and Counter-Terrorist Agencies) will probably become a bit more paranoid , their work becomes tougher.
Patch | Status |
---|---|
Daemon | On Review |
Lib Ring Client (LRC) | On Review |
Gnome client | On review |
Remove unused code | Merged |
Information | Details | Done? |
---|---|---|
Call ID | The identification number of the call | Yes |
Resolution | Local and remote | Yes |
Framerate | Local and remote | Yes |
Codec | Audio and video in local and remote | Yes |
Bandwidth | Download and upload | No |
Performance use | CPU, GPU, RAM | No |
Security level | In SIP call | No |
Connection time | No | |
Packets lost | No |
Patch | Status |
---|---|
Daemon | Merged |
Lib Ring Client (LRC) | On Review |
Gnome client | On Review |
Remove unused code | Merged |
Information | Details | Done? |
---|---|---|
Call ID | The identification number of the call | Yes |
Resolution | Local and remote | Yes |
Framerate | Local and remote | Yes |
Codec | Audio and video in local and remote | Yes |
Bandwidth | Download and upload | No |
Performance use | CPU, GPU, RAM | No |
Security level | In SIP call | No |
Connection time | No | |
Packets lost | No |
Publisher: | Faber and Faber |
Copyright: | 2012, 2013 |
Printing: | 2014 |
ISBN: | 0-86547-806-6 |
Format: | Trade paperback |
Pages: | 397 |
2004/05/27 Book Store
Expenses:Books $20.00
Liabilities:Visa
starting to use hledger
Now as a Haskell guy, I was immediately drawn to
the Haskell clone, hledger. It's nice that there
are two (mostly) compatable implementations of ledger too. So from here on,
I'll be talking about hledger.
I sat down and built a hledger setup for myself the other day.
I started by converting the GnuCash books I have been keeping up-to-date,
for a small side business (a rental property). It quickly turned into
something like programming, in the best way, as I used features like:
print
, to a interactive interface.hledger stats
says I have 3700 transactions on file,
which is not bad for what was just a few hours work yesterday.
One problem is hledger's gotten a little slow with this many transactions. It
takes 5 seconds to get a balance. The ledger
program, written in C, is
reportedly much faster. hledger recently had a O(n^2)
slowdown fixed,
which makes me think it's probably only starting to be optimised. With
Haskell code, you can get lucky and get near C (language, not speed of
light) performace without doing much, or less lucky and get not much better
than python performance until you dive into optimising. So there's hope.
harnessing haskell
If there's one place hledger misses out on being a state of the art modern
Unix program, it's in the rules files that are used to drive CSV
imports. I found these really hard to use; the manual notes that "rules
file parse errors are not the greatest"; and it's just really inflexible.
I think the state of the art would be to use a Domain Specific Language here.
For both my Amazon and PayPal imports I had CVS data something like:
date, description, amount, fees, gross
I want to take the feeds into account, and make a split transaction, like this:
date description
assets:accounts:PayPal $9.90
expenses:transaction fees:PayPal $0.10
income:misc:PayPal -$10.00
This does not seem possible with the rules file. I also wanted to combine
multiple CVS lines, to do with currency conversions, into a single
transaction, and couldn't.
The problem is that the rules file is an ad-hoc format, not a fully
programmable one. If instead, hledger's rules files were compiled into
standalone haskell programs that performed the import, arbitrarily
complicated conversions like the above could be done.
So, I'm thinking about something like this for a DSL.. I doubt I'll get
much further than this, since I have a hacked together multi-pass importer
that meets my basic needs. Still, this would be nice, and being able to
think about adding thing kind of thing to a program cleanly is one of the
reasons I reach for the Haskell version when possible these days.
First, here's part of one of my two paypal import rules files
(the other one extracts the transaction fees):
amount-field 7
date-field 0
description-field %(3) - %(4) - %(11)
base-account assets:accounts:PayPal
Bank Account
assets:accounts:checking
.*
expenses:misc:PayPal
That fills out the basic fields, and makes things with "Bank Account"
in their description be categorised as bank transfers.
Here's how it'd look as Haskell, carefully written to avoid the $
operator that's more than a little confusing in this context. :)
main :: IO () main = convert paypalConveter paypalConverter :: [CSVLine] -> [Maybe Transaction] paypalConverter = map convert where convert = do setAmount =<< field 7 setDate =<< field 0 setDescription =<< combine " - " [field 3, field 4, field 11] defaultAccounts "assets:accounts:PayPal" ==> "expenses:misc:PayPal" inDescription "Bank Account" ? "assets:accounts:PayPal" ==> "assets:accounts:checking"That seems like something non-haskell people could get their heads around, especially if they didn't need to write the boilerplate function definitions and types at the top. But I may be biased. :) Internally, this seems to be using a combination Reader and Writer monad that can get at fields from a CSV line and build up a Transaction. But I really just made up a simple DSL as I went along and thew in enough syntax to make it seem practical to implement. :) Of course, a Haskell programmer can skip the monads entirely, or use others they prefer. And could do arbitrarily complicated stuff during imports, including building split transactions, and combining together multiple related CVS lines into a single transaction.
Cipla cut price of its kidney cancer drug Sorafenib, which is sold under brand name Nexavar by multi-national Bayer to Rs 6,840 for a month's supply, from around Rs 28,000 earlier. Its lung cancer drug Gestinib, which is sold under brand name Iressa by AstraZeneca will cost Rs 4,250, versus Rs 10,200 earlier, and price of Temozolamide used to treat brain tumour, has been reduced by Rs 15,000 to Rs 5,000.
India's Patent Office recently issued a compulsory licence allowing Natco to make a generic copy of Sorafenib, on the payment of a royalty to Bayer, which sells the drug at around Rs 2 lakh.
Domestic sales account for 46-47% of Cipla's total sales and of that the cancer drugs portfolio is a very small portion, so these price cuts are unlikely to have any major impact on its revenue, Hitesh Mahida of Fortune Equity Brokers told moneycontrol.com
"Cipla's idea seems to be to create disruption in the market, increase its market share..." the analyst says.
Swiss pharma major Roche had earlier this year signed a manufacturing deal with India's Emcure Pharma so that its anti-cancer drugs Herceptin and MabThera could be made in India at affordable prices. Analysts say Cipla's move to slash prices could in future deter some MNCs from launching their drugs in India at all, but some may also look at doing deals like the one struck by Roche.
Meanwhile, shares of pharma major Cipla surged over 3% on Friday after brokerage CLSA upgraded the stock to "outperform" from "underperform," saying, Cipla would be strongest beneficiaries of a weakening rupee.
The rupee has been sliding sharply against the US dollar in recent days and hit over four month low of around Rs 53.78 earlier in trade.
"We expect improving margins over the coming quarters on back of a weak rupee and a low base. We expect strong operating profit growth over coming quarters led by margin expansion and high margin product supplies," CLSA's Hemant Bakhru said.
The US Food and Drugs Administration has approved Meda's drug Dymista for allergic rhinitis and the product is widely expected to reach USD 300-500 million in annual sales over the coming years. The analyst says Cipla being a partner, will benefit through product supplies over a longer term.
"Apart from approval (outside North America) related milestone payment (US$5m), we expect gradual increase in Cipla s sales from product related supplies to Meda. Assuming Cipla supplies product at 10-15% of sales, it could earn US$50-75m at peak sales," Bakhru said.
Additionally, a low base in domestic formulations could result in reasonable India growth, he adds.
Cipla shares were up 2.8% at Rs 326.60 on NSE in noon trade.
Next.